Table 5. The correlation between BRCA1 and ERCC1 expressions in long-term outcomes.
| Expression | 3-year OS (%) | P1 value | 3-year FFS (%) | P1 value | 3-year LR-FFS (%) | P1 value | 3-year D-FFS (%) | P1 value | MST (Months) | |
|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | ||||||||||
| + | 72.8(94/129) | 0.004 | 73.6(95/129) | 0.048 | 79.8(102/129) | 0.085 | 82.2(106/129) | 0.028 | 30.8(28.8-31.9) | |
| - | 81.9(59/72) | 83.3(60/72) | 88.9(64/72) | 88.9(64/72) | 34.3(33.9-35.3) | |||||
| ERCC1 | ||||||||||
| + | 77.8(98/136) | 0.009 | 72.7(99/136) | 0.036 | 77.9(106/136) | 0.044 | 82.4(112/136) | 0.036 | 31.6(29.8-32.6) | |
| - | 84.6(55/65) | 87.6(57/65) | 92.3(60/65) | 89.2(58/65) | 34.8(32.7-35.8) | |||||
| BRCA1 | ERCC1 | |||||||||
| + | + | 75.7(78/103) | 0.001 | 62.1(64/103) | 0.002 | 76.6(79/103) | 0.163 | 79.6(82/103) | 0.004 | 30.5(28.5-31.7) |
| - | - | 100(39/39) | 100(39/39) | 100(39/39) | 100(39/39) | 36(36-36) | ||||
| + | - | 81.0(21/26) | 84.6(22/26) | 92.3(24/26) | 84.6(22/26) | 34.6(32.4-35.1) | ||||
| - | + | 78.7(26/33) | 72.7(24/33) | 81.8(27/33) | 90.9(30/33) | 32.2(29.5-34.9) | ||||
1: Statistical analysis was estimated with log-rank, and P < 0.05 was considered statistically significant; OS: overall survival; FFS: failure-free survival; LR-FFS: locoregional failure-free survival; D-FFS: distant failure-free survival.